Saudi Arabia Allergy Therapeutics Market Analysis

Saudi Arabia Allergy Therapeutics Market Executive Summary

Saudi Arabia allergy therapeutics market was valued at $394 Mn in 2022 and is estimated to reach $725 Mn in 2030, exhibiting a CAGR of 7.9% during the forecast period.

The immune system's sensitivity to harmless environmental substances, or allergens, causes allergies. These allergens can include common dietary triggers like milk, eggs, soy, and almonds, as well as dust mites, pollen, and mold. Allergic reactions ranging from mild to severe can cause symptoms such as stinging eyes and runny noses, while anaphylaxis, a severe reaction, can induce coma and difficulty breathing. Strategies like immunotherapy, avoiding allergens, and using prescription medications like nasal corticosteroids and antihistamines can all be used to control allergies.

In Saudi Arabia, allergies are becoming more and more common, affecting a significant percentage of people of all ages. According to estimates, between 30% and 40% of Saudis suffer from allergies, which is a significant increase. Particular allergies are noteworthy; among the most common is allergic rhinitis, which affects around 35%–40% of people and causes symptoms like congestion, runny noses, itchy eyes, and sneezing, which severely lowers quality of life. 7%–10% of children and 3%–4% of adults suffer from food allergies, which can cause severe responses and require emergency medical intervention. 5%–10% of people have skin allergies, mostly eczema, and 8% of Saudis have lung allergies, including asthma, which are brought on by allergens like mold, dust mites, and pollen. Allergies are becoming more common due to a combination of genetic, environmental, and lifestyle factors.

Research projects aimed at understanding the prevalence and triggers of allergies are actively supported by the King Abdulaziz Science and Technology City (KACST). With the ultimate goal of developing treatment plans that are appropriate for Saudi Arabian culture, the focus is on promoting a greater understanding of the country. Pharmaceutical companies like Al-Hayat Pharmaceutical Company and Tabuk Pharmaceutical Manufacturing Company are making major contributions to the development of allergy therapies within the local pharmaceutical scene. These organizations are allocating funds to research and development projects with the goal of producing allergy treatments, including generic versions of already-approved pharmaceuticals.

Market Dynamics

Market Growth Drivers

Changing Lifestyles: An increase in allergies can be attributed to changes in the environment, urbanization, and lifestyle, which increase the demand for allergy treatment drugs. An increased frequency of allergic disorders may result from variables such as pollution, dietary modifications, and allergen exposure.

Increased Awareness and Diagnosis: People are more likely to seek treatment when allergies are identified sooner and with greater precision, thanks to improved diagnostic capabilities and public awareness campaigns. Due to the rising demand for allergy treatment medications brought on by this greater awareness, the market is expanding.

Increasing Prevalence of Allergies: The need for allergy treatment medications is mostly driven by the increased prevalence of allergic conditions among citizens, including food allergies, skin allergies, and respiratory allergies.

Market Restraints

Regulatory Hurdles: If the licensing process for innovative medications and therapies is delayed, patients might not have timely access to innovative treatments because of the stringent regulatory protocols that need to be followed. This delay in licensing process can hinder the growth of the market.

Treatment Compliance and Adherence: Consistent adherence is essential for allergy therapies to be effective, particularly long-term regimens like immunotherapy. Ineffective patient adherence caused by costs, difficulties, or side effects may lessen therapy efficacy and obstruct market growth.

High Cost of Treatment: A considerable percentage of the population cannot afford many of the modern and successful allergy medicines, such as biologics and sublingual immunotherapy, due to their high cost. This may restrict patients access to the best possible care and market penetration.

Healthcare Policies and Regulatory Landscape

The Saudi Food and Drug Authority (SFDA), the main regulatory organization in charge of ensuring the efficacy, safety, and quality of pharmaceuticals, is in charge of regulating the legal framework for allergy treatment medications in Saudi Arabia. Approval from the SFDA, which oversees drug registration and safety standard compliance, is required for companies looking to market allergy therapy products. The pricing approval procedure is also influenced by the SFDA, which has an effect on the accessibility and affordability of allergy therapy drugs. The SFDA must approve clinical studies for novel medications, including allergy therapies, in order to guarantee ethical and safety requirements. Pharmaceutical product quality standards could be set by the Saudi Arabian Standard Organization (SASO), which would add to the regulatory environment as a whole. The environment for the import, sale, and distribution of medications used to treat allergies is further shaped by rules governing pharmacy practices, customs, and government health policy.

Competitive Landscape

Key Players

• Sanofi
• Novartis
• GlaxoSmithKline (GSK)
• AstraZeneca
• Merck & Co.
• Johnson & Johnson
• Roche
• Teva Pharmaceutical Industries
• ALK-Abelló
• Stallergenes Greer